KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

被引：205

作者：

Ambrogio, Chiara ^{[1
]}

Kohler, Jens ^{[1
]}

Zhou, Zhi-Wei ^{[2
,3
]}

Wang, Haiyun ^{[4
]}

Paranal, Raymond ^{[1
]}

Li, Jiaqi ^{[1
]}

Capelletti, Marzia ^{[1
]}

Caffarra, Cristina ^{[1
]}

Li, Shuai ^{[1
]}

Lv, Qi ^{[4
]}

Gondi, Sudershan ^{[2
,3
]}

Hunter, John C. ^{[2
,3
]}

Lu, Jia ^{[2
,3
]}

Chiarle, Roberto ^{[5
,6
,7
]}

Santamaria, David ^{[8
]}

Westover, Kenneth D. ^{[2
,3
]}

Janne, Pasi A. ^{[1
,9
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA

[4] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China

[5] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA

[6] Harvard Med Sch, Boston, MA 02115 USA

[7] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy

[8] Univ Bordeaux, INSERM, U1218, ACT Lab,IECB, F-33600 Pessac, France

[9] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02215 USA

来源：

CELL | 2018年 / 172卷 / 04期

基金：

中国国家自然科学基金;

关键词：

CELL LUNG-CANCER; RAS FORMS DIMERS; WILD-TYPE RAS; THERAPEUTIC STRATEGY; PROLIFERATION; DOCETAXEL; PROTEINS; SURVIVAL; SITE;

D O I：

10.1016/j.cell.2017.12.020

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and underlies resistance to MEK inhibition. These effects are abrogated when wild-type KRAS is replaced by KRAS(D154Q), a mutant that disrupts dimerization at the alpha 4-alpha 5 KRAS dimer interface without changing other fundamental biochemical properties of KRAS, both in vitro and in vivo. Moreover, dimerization has a critical role in the oncogenic activity of mutant KRAS. Our studies provide mechanistic and biological insights into the role of KRAS dimerization and highlight a role for disruption of dimerization as a therapeutic strategy for KRAS mutant cancers.

引用

页码：857 / +

页数：27

共 50 条

[31] A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer [J].

Deming, Dustin A. ;

Cavalcante, Ludmila L. ;

Lubner, Sam J. ;

Mulkerin, Daniel L. ;

LoConte, Noelle K. ;

Eickhoff, Jens C. ;

Kolesar, Jill M. ;

Fioravanti, Suzanne ;

Greten, Tim F. ;

Compton, Kathryn ;

Doyle, Austin G. ;

Wilding, George ;

Duffy, Austin ;

Liu, Glenn .

INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) :168-175

[32] Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer [J].

Broutin, Sophie ;

Stewart, Adam ;

Thavasu, Parames ;

Paci, Angelo ;

Bidart, Jean-Michel ;

Banerji, Udai .

BRITISH JOURNAL OF CANCER, 2016, 115 (05) :549-552

[33] BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition [J].

Andrews, Miles C. ;

Behren, Andreas ;

Chionh, Fiona ;

Mariadason, John ;

Vella, Laura J. ;

Do, Hongdo ;

Dobrovic, Alexander ;

Tebbutt, Niall ;

Cebon, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) :E448-E451

[34] Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts [J].

Rosen, Joshua C. ;

Weiss, Jessica ;

Pham, Nhu-An ;

Li, Quan ;

Martins-Filho, Sebastiao N. ;

Wang, Yuhui ;

Tsao, Ming-Sound ;

Moghal, Nadeem .

TRANSLATIONAL ONCOLOGY, 2021, 14 (10)

[35] Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer [J].

Kitai, Hidenori ;

Ebi, Hiromichi ;

Tomida, Shuta ;

Floros, Konstantinos V. ;

Kotani, Hiroshi ;

Adachi, Yuta ;

Oizumi, Satoshi ;

Nishimura, Masaharu ;

Faber, Anthony C. ;

Yano, Seiji .

CANCER DISCOVERY, 2016, 6 (07) :754-769

[36] Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer [J].

Li, Yong ;

He, Yi ;

Peng, Junya ;

Su, Zhendong ;

Li, Zeyao ;

Zhang, Bingjie ;

Ma, Jing ;

Zhuo, Meilian ;

Zou, Di ;

Liu, Xinde ;

Liu, Xinhong ;

Wang, Wenze ;

Huang, Dan ;

Xu, Mengyue ;

Wang, Jianbin ;

Deng, Haiteng ;

Xue, Jing ;

Xie, Wei ;

Lan, Xun ;

Chen, Mo ;

Zhao, Yupei ;

Wu, Wenming ;

David, Charles J. .

NATURE CANCER, 2021, 2 (01) :49-+

[37] STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma [J].

Skoulidis, Ferdinandos ;

Goldberg, Michael E. ;

Greenawalt, Danielle M. ;

Hellmann, Matthew D. ;

Awad, Mark M. ;

Gainor, Justin F. ;

Schrock, Alexa B. ;

Hartmaier, Ryan J. ;

Trabucco, Sally E. ;

Gay, Laurie ;

Ali, Siraj M. ;

Elvin, Julia A. ;

Singal, Gaurav ;

Ross, Jeffrey S. ;

Fabrizio, David ;

Szabo, Peter M. ;

Chang, Han ;

Sasson, Ariella ;

Srinivasan, Sujaya ;

Kirov, Stefan ;

Szustakowski, Joseph ;

Vitazka, Patrik ;

Edwards, Robin ;

Bufill, Jose A. ;

Sharma, Neelesh ;

Ou, Sai-Hong I. ;

Peled, Nir ;

Spigel, David R. ;

Rizvi, Hira ;

Aguilar, Elizabeth Jimenez ;

Carter, Brett W. ;

Erasmus, Jeremy ;

Halpenny, Darragh F. ;

Plodkowski, Andrew J. ;

Long, Niamh M. ;

Nishino, Mizuki ;

Denning, Warren L. ;

Galan-Cobo, Ana ;

Hamdi, Haifa ;

Hirz, Taghreed ;

Tong, Pan ;

Wang, Jing ;

Rodriguez-Canales, Jaime ;

Villalobos, Pamela A. ;

Parra, Edwin R. ;

Kalhor, Neda ;

Sholl, Lynette M. ;

Sauter, Jennifer L. ;

Jungbluth, Achim A. ;

Mino-Kenudson, Mari .

CANCER DISCOVERY, 2018, 8 (07) :822-835

[38] Exploiting MCL1 Dependency with Combination MEK+MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer [J].

Nangia, Varuna ;

Siddiqui, Faria M. ;

Caeriepeel, Sean ;

Timonina, Daria ;

Bilton, Samantha J. ;

Phan, Nicole ;

Gomez-Caraballo, Maria ;

Archibald, Hannah L. ;

Li, Chendi ;

Fraser, Cameron ;

Rigas, Diamanda ;

Vajda, Kristof ;

Ferris, Lorin A. ;

Lanuti, Michael ;

Wright, Cameron D. ;

Raskin, Kevin A. ;

Cahill, Daniel P. ;

Shin, John H. ;

Keyes, Colleen ;

Sequist, Lecia, V ;

Piotrowska, Zofia ;

Farago, Anna F. ;

Azzoli, Christopher G. ;

Gainor, Justin F. ;

Sarosiek, Kristopher A. ;

Brown, Sean P. ;

Coxon, Angela ;

Benes, Cyril H. ;

Hughes, Paul E. ;

Hata, Aaron N. .

CANCER DISCOVERY, 2018, 8 (12) :1598-1613

[39] XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer [J].

Principe, Daniel R. ;

Xiong, Rui ;

Li, Yangfeng ;

Pham, Thao N. D. ;

Kamath, Suneel D. ;

Dubrovskyi, Oleksii ;

Ratia, Kiira ;

Huang, Fei ;

Zhao, Jiong ;

Shen, Zhengnan ;

Thummuri, Dinesh ;

Zhou Daohong ;

Underwood, Patrick W. ;

Trevino, Jose ;

Munshi, Hidayatullah G. ;

Thatcher, Gregory R. J. ;

Rana, Ajay .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (04)

[40] Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models [J].

Pia Morelli, M. ;

Tentler, John J. ;

Kulikowski, Gillian N. ;

Tan, Aik-Choon ;

Bradshaw-Pierce, Erica L. ;

Pitts, Todd M. ;

Brown, Amy M. ;

Nallapareddy, Sujatha ;

Arcaroli, John J. ;

Serkova, Natalie J. ;

Hidalgo, Manuel ;

Ciardiello, Fortunato ;

Gail Eckhardt, S. .

CLINICAL CANCER RESEARCH, 2012, 18 (04) :1051-1062

← 1 2 3 4 5 →